DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH. et al.
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Blood 2019;
134: 1024-36
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.